Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Da Jun Zhao
Chief executive officer
CN¥2.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 22.3yrs |
| CEO ownership | 1.5% |
| Management average tenure | no data |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥102m |
| Dec 31 2023 | n/a | n/a | CN¥109m |
| Sep 30 2023 | n/a | n/a | CN¥191m |
| Jun 30 2023 | n/a | n/a | CN¥242m |
| Mar 31 2023 | n/a | n/a | CN¥142m |
| Dec 31 2022 | CN¥2m | n/a | CN¥138m |
| Sep 30 2022 | n/a | n/a | CN¥132m |
| Jun 30 2022 | n/a | n/a | CN¥112m |
| Mar 31 2022 | n/a | n/a | CN¥213m |
| Dec 31 2021 | CN¥5m | CN¥2m | CN¥213m |
| Sep 30 2021 | n/a | n/a | CN¥198m |
| Jun 30 2021 | n/a | n/a | CN¥201m |
| Mar 31 2021 | n/a | n/a | CN¥188m |
| Dec 31 2020 | CN¥3m | CN¥1m | CN¥165m |
| Sep 30 2020 | n/a | n/a | CN¥191m |
| Jun 30 2020 | n/a | n/a | CN¥165m |
| Mar 31 2020 | n/a | n/a | CN¥204m |
| Dec 31 2019 | CN¥3m | CN¥1m | CN¥227m |
| Sep 30 2019 | n/a | n/a | CN¥151m |
| Jun 30 2019 | n/a | n/a | CN¥151m |
| Mar 31 2019 | n/a | n/a | CN¥91m |
| Dec 31 2018 | CN¥2m | CN¥1m | CN¥112m |
| Sep 30 2018 | n/a | n/a | CN¥95m |
| Jun 30 2018 | n/a | n/a | CN¥78m |
| Mar 31 2018 | n/a | n/a | CN¥77m |
| Dec 31 2017 | CN¥1m | CN¥1m | CN¥75m |
Compensation vs Market: Da Jun's total compensation ($USD307.31K) is below average for companies of similar size in the Hong Kong market ($USD482.26K).
Compensation vs Earnings: Da Jun's compensation has been consistent with company performance over the past year.
CEO
Da Jun Zhao (53 yo)
22.3yrs
Tenure
CN¥2,224,000
Compensation
Mr. Da Jun Zhao has been an Executive Director at Taizhou SPH Pharmaceutical Co., Ltd. since January 2002. Mr. Zhao Co-Founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.in November 1996 and ser...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22.3yrs | CN¥2.22m | 1.51% CN¥ 99.9m | |
| CFO, Deputy GM | less than a year | CN¥2.02m | 0.20% CN¥ 13.3m | |
| Non-Executive Director | 11yrs | no data | no data | |
| Member of Supervisory Committee | no data | no data | no data | |
| Non Executive Director | 11.9yrs | no data | no data | |
| Independent Chairman of Supervisory Committee | 6.9yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Member of Supervisory Committee | no data | no data | 0.0038% CN¥ 249.4k |
4.0yrs
Average Tenure
53yo
Average Age
Experienced Board: 1349's board of directors are considered experienced (4 years average tenure).